Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles

Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of therapeutic agents of any kind to PDAC in parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Matthew S., Krasnick, Bradley A., Pan, Hua, Zhang, Xiuli, Bi, Ye, Brooks, Candace, Wetzel, Christopher, Sankpal, Narendra, Fleming, Timothy, Goedegebuure, S. Peter, DeNardo, David G., Gillanders, William E., Hawkins, William G., Wickline, Samuel A., Fields, Ryan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677667/
https://www.ncbi.nlm.nih.gov/pubmed/31413817
http://dx.doi.org/10.18632/oncotarget.27109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677667/
https://www.ncbi.nlm.nih.gov/pubmed/31413817
http://dx.doi.org/10.18632/oncotarget.27109

Ejemplares similares